1. United States of America Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
FlashZero Corp.

FlashZero Corp.

FZRO
FlashZero Corp.US flagOther OTC
2.00
USD
- -
- -
346.20MMarket Cap
FlashZero Corp.
FZRO
(Other OTC)

Recent

price

2.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2005
2006
2007
2008
2009
TTM
FRC
- -
- -
766
- -
- -
- -
Revenue per Share
- -
- -
-1,165,988
-401,629
-269,793
-341,612
Basic EPS, GAAP
- -
- -
-15,487
-742,563
-104
-104
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-5,285,000
-5,669,712
-5,939,505
-6,078,772
Book Value per Share
- -
- -
-2,920,340
-1,544,672
-1,814,465
-1,953,732
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
-121,907.89
-146,466.84
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-124,227.89
-152,217.75
- -
- -
- -
Profit Margin (%)
- -
-1
-2
-2
-2
-2
Working Capital
- -
- -
- -
- -
- -
- -
LT Debt
-1
-2
-3
-2
-2
-2
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'09
Dec'09
Mar'10
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
310
250
190

Working Capital

FRC

•

in mil. unless spec.
Sep'09
Dec'09
Mar'10
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
2
Payables & Accruals
2
2
2
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
17.47%
Free Cash Flow
- -
- -
-99.99%
Net Income, GAAP
- -
- -
-32.83%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
-176,452
-128,899
-56,146
- -
-401,629
2009
-67,449
-67,448
-67,449
- -
-269,793
2010
-139,267
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2008
- -
- -
- -
- -
- -
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
Similar Companies
Metro Inc. (MTRI)
Iron Horse Acquisitions Corp. II Rights (IRHOR)
QMIS Finance Securities Corporation (QMIS)
Forwardly Inc. (FORW)
Public Company Management Corp. (PCMC)
TZP Strategies Acquisition Corp. (TZPSW)
Business
FlashZero Corp. (FZRO), formerly known as The Children's Internet Inc., operates as a pharmaceutical wholesaler and manufacturer of medical technology products, with a focus on healthcare distribution and innovative medical solutions; it offers injectors, pistons, hose systems, PCR tests, medicines, and gloves for applications in medicine, radiology, cardiology, and radiation therapy. Incorporated in 1996 and headquartered in Neuss, Germany, the company conducts operations internationally, primarily in Germany and other global markets, serving healthcare professionals, clinics, hospitals, and wholesalers as part of the CS Group. In September 2023, its subsidiary CS Diagnostics Corp. acquired 100% of CS Protect-Hydrogel, including intellectual property, distribution rights, and patents, a ready-to-use sterile hydrogel for radiotherapy in cancers such as prostate, cervical, esophageal, bladder, and breast, offering advantages over competitors like reduced preparation risks, broader applications, and cost efficiencies. The company changed its name from FlashZero Corp. to CS Diagnostics Corp. in August 2023, marking a strategic shift from prior software and internet commerce activities to medical technology and pharmaceuticals. Recent developments include a Regulation D Rule 506(c) investment offering launched in October 2025 to fund commercialization of CS Protect-Hydrogel and MEDUSA infection control products, alongside a $5 million loan letter of intent and preferred-to-common share conversions in October 2025 to strengthen its path to uplisting and profitability.